Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadVax for r/r Hodgkin's Lymphoma
NCT03495713Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in Hodgkin lymphoma (HL), sponsored by Abramson Cancer Center. Primary endpoint: Complete Response Rate at 25 weeks. Started Nov 2018; status: terminated.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03495713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495713.